Ginkgo bioworks provides business updates at j.p. morgan healthcare conference

Expects to meet 2023 new program and revenue guidance ranges ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as ginkgo sees operational efficiencies in the business strong growth among blue chip pharma and biotech ("biopharma") customers including pfizer, novo nordisk, merck and boehringer ingelheim management to highlight updates today at the 42nd annual j.p. morgan healthcare conference at 9:45 a.m.
DNA Ratings Summary
DNA Quant Ranking